annual meeting program - American Society of Clinical Oncology

2:00 PM - 6:00 PM
GENERAL POSTER SESSION
Saturday, June 5, 2010
Gynecologic Cancer
Location: S Hall A2
Tracks(s): Gynecologic Cancer
Brd. 45A Use of 99mTc-EC20 (a folate-targeted imaging agent) to predict response to
therapy with EC145 (folate-targeted therapy) in advanced ovarian cancer.
(Abstract #5034)
J. T. Symanowski, A. H. Maurer, R. W. Naumann, N. P. Shah, D. Morgenstern,
R. A. Messmann
Brd. 45B Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in
patients with LHRH receptor-positive platinum resistant ovarian cancer.
(Abstract #5035)
G. Emons, S. Tomov, P. Harter, J. Sehouli, P. Wimberger, A. Staehle,
L. C. Hanker, F. Hilpert, P. Dall, C. Gruendker, AGO Study Group
Brd. 45C Abagovomab maintenance therapy in patients with epithelial ovarian cancer
after complete response (CR) post-first-line chemotherapy (FLCT):
Preliminary results of the randomized, double-blind, placebo-controlled,
multicenter MIMOSA trial. (Abstract #5036)
P. Sabbatini, J. S. Berek, A. Casado, K. Cwiertka, T. Pinter, A. Pluzanska,
G. Scambia, E. Pujade-Lauraine, J. B. Vermorken, J. Pfisterer
Brd. 45D Tolerability and pharmacokinetics of intraperitoneal carboplatin and
paclitaxel with intravenous bevacizumab. (Abstract #5037)
C. N. Krasner, M. Seiden, M. Roche, M. A. Morgan, U. Matulonis, J. Wolf,
C. Drescher, R. D. Alvarez, D. K. Armstrong, J. G. Supko
Brd. 45E A phase II study of sunitinib in recurrent or metastatic endometrial
carcinoma: A trial of the Princess Margaret Hospital, The University of
Chicago, and California Cancer Phase II Consortia. (Abstract #5038)
R. Correa, H. Mackay, H. W. Hirte, R. Morgan, S. Welch, G. F. Fleming, L. Wang,
C. Blattler, S. P. Ivy, A. M. Oza
Brd. 45F Intraoperative immunotherapy with the trifunctional antibody catumaxomab
in patients with ovarian cancer: Results from a phase II study. (Abstract
#5039)
R. Chekerov, A. Reinthaller, D. Reimer, T. Reimer, L. Angleitner-Boubenizek,
M. Halfen, H. Lindhofer, I. Braicu, G. Oskay-Özcelik, J. Sehouli
Brd. 45G The use of pegylated liposomal doxorubicin with hyperthermic
intraperitoneal chemotherapy (HIPEC) in patients undergoing cytoreductive
surgery (CS) for peritoneal carcinomatosis of ovarian origin. (Abstract #5040)
M. De Tursi, E. Salvatorelli, C. Carella, N. Bianco, R. Massari, R. Sacco, P. Menna,
G. Minotti, S. Iacobelli
Brd. 45H Preliminary experience with the use of chemotherapy (CT) following
treatment with olaparib, a poly(ADP-ribose) polymerase inhibitor (PARPi), in
patients with BRCA1/2-deficient ovarian cancer (BDOC). (Abstract #5041)
J. Ang, T. A. Yap, P. Fong, C. P. Carden, D. S. Tan, J. Hanwell, J. Carmichael,
J. S. De Bono, M. E. Gore, S. B. Kaye
Brd. 46A Exposure-response relationships of AMG 386 in combination with weekly
paclitaxel in advanced ovarian cancer: Population pharmacokinetic/
pharmacodynamic (PK/PD) modeling to facilitate phase III dose selection.
(Abstract #5042)
J. Lu, E. Rasmussen, L. Navale, M. Kuchimanchi, E. Hurh, B. Y. Karlan,
I. B. Vergote, D. E. Stepan, D. M. Weinreich, Y. Sun
Brd. 46B Pegylated liposomal doxorubicin (PLD) treatment for recurrent epithelial
ovarian cancer (rEOC): Implications of BRCA mutations. (Abstract #5043)
T. Safra, L. Borgato, M. Nicoletto, L. Rolnitzky, J. Curtin, R. Geva, S. Peles,
T. Grenader, A. Gabizon, F. Muggia
169
SATURDAY